These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1346 related items for PubMed ID: 12444544
1. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE. Oncogene; 2002 Nov 21; 21(53):8075-88. PubMed ID: 12444544 [Abstract] [Full Text] [Related]
2. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Oncogene; 2002 Dec 12; 21(57):8804-16. PubMed ID: 12483533 [Abstract] [Full Text] [Related]
3. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, Boschelli F. Cancer Res; 2003 Jan 15; 63(2):375-81. PubMed ID: 12543790 [Abstract] [Full Text] [Related]
4. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K. Cancer Res; 2002 Oct 15; 62(20):5761-9. PubMed ID: 12384536 [Abstract] [Full Text] [Related]
7. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover. Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T. Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551 [Abstract] [Full Text] [Related]
9. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. Cancer Res; 1996 Aug 01; 56(15):3589-96. PubMed ID: 8758931 [Abstract] [Full Text] [Related]
11. Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells. Gamas P, Marchetti S, Puissant A, Grosso S, Jacquel A, Colosetti P, Pasquet JM, Mahon FX, Cassuto JP, Auberger P. Leukemia; 2009 Aug 01; 23(8):1500-6. PubMed ID: 19340007 [Abstract] [Full Text] [Related]
14. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. Kindler T, Breitenbuecher F, Kasper S, Stevens T, Carius B, Gschaidmeier H, Huber C, Fischer T. Leukemia; 2003 Jun 01; 17(6):999-1009. PubMed ID: 12764361 [Abstract] [Full Text] [Related]
15. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients. Gutiérrez-Castellanos S, Cruz M, Rabelo L, Godínez R, Reyes-Maldonado E, Riebeling-Navarro C. Eur J Haematol; 2004 Apr 01; 72(4):231-8. PubMed ID: 15089759 [Abstract] [Full Text] [Related]
16. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M. Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214 [Abstract] [Full Text] [Related]
18. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Hoover RR, Gerlach MJ, Koh EY, Daley GQ. Oncogene; 2001 Sep 13; 20(41):5826-35. PubMed ID: 11593388 [Abstract] [Full Text] [Related]
19. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148. Dan S, Naito M, Tsuruo T. Cell Death Differ; 1998 Aug 13; 5(8):710-5. PubMed ID: 10200527 [Abstract] [Full Text] [Related]
20. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Rahmani M, Nguyen TK, Dent P, Grant S. Mol Pharmacol; 2007 Sep 13; 72(3):788-95. PubMed ID: 17595328 [Abstract] [Full Text] [Related] Page: [Next] [New Search]